Re:GLP-1 drugs led to weight loss and reversed depression-li...
by JumpCrisscross on Saturday June 27, 2026 @10:41PM
(#48703852)
> Third party private healthcare decisions are almost non-existant in the US due to the payment systems
The payment part is almost entirely pushing against GLP-1 agonists. Nobody has a long-term financial stake in patient costs to care that lifetime costs will likely be lower; insurers are just looking at the next couple years against expected churn. Another cost of tying health insurance to employment.
That said, 2026 US GLP-1 healthcare sales projections run between 60 and 100 billion [1]. it will be interesting to see if these miricle drugs can really provide that much benefit/offset that much cost.
For comparison, Medicare part D is ~150 billion in its entirety. https://evolvancemarketresearch.com/reports/glp-1-weight-los...